Kymera Therapeutics, Inc.

20.55 USD
-0.72 (-3.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kymera Therapeutics, Inc. stock is up 42.71% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
02 Nov 14:46 15 Dec, 2023 25.00 PUT 20 20

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases. IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the. treatment of hematologic malignancies and solid tumors.